



General Assembly

Substitute Bill No. 270

February Session, 2010

* ____SB00270GL____042910____ *

**AN ACT CONCERNING THE PROHIBITION OF CERTAIN GIFTS FROM
PHARMACEUTICAL AND MEDICAL DEVICE MANUFACTURING
COMPANIES TO HEALTH CARE PROVIDERS.**

Be it enacted by the Senate and House of Representatives in General Assembly convened:

1 Section 1. (NEW) (*Effective July 1, 2010*) As used in sections 1 to 7,
2 inclusive, of this act:

3 (1) "Biologic" means a "biological product", as defined in 42 USC
4 262(i), as amended from time to time, that is regulated as a drug under
5 the federal Food, Drug and Cosmetic Act, 21 USC 301 et seq.;

6 (2) "Bona fide services" means an arrangement for services
7 including, but not limited to: (A) Research, (B) participation on
8 advisory boards, (C) collaboration with nonprofit organizations, as
9 described in Section 501(c)(3) of the Internal Revenue Code of 1986, or
10 any subsequent corresponding internal revenue code of the United
11 States, as from time to time amended, that are dedicated to the
12 promotion of health and the prevention of disease, and (D)
13 presentations at pharmaceutical or medical device manufacturing
14 company-sponsored medical education and training, including the
15 federal Food and Drug Administration required education and
16 training involved in producing safe and effective medical devices,
17 provided such arrangement is formalized in a written agreement
18 specifying the services to be provided, based on the fair market value

19 of the services and characterized by the following factors: (i) A
20 legitimate need for the services clearly identified in advance; (ii) a
21 connection between the competence and expertise of the health care
22 provider and the purpose of the arrangement; (iii) the number of
23 health care providers retained is not greater than the number
24 reasonably necessary to achieve the identified purpose; (iv) the
25 retaining pharmaceutical or medical device manufacturing company
26 maintains records concerning the arrangement and makes appropriate
27 use of the services provided by the health care provider; (v) the venue
28 and circumstances of any meeting with the health care provider is
29 conducive to the services and activities related to the services are the
30 primary focus of the meeting; and (vi) the decision to retain a health
31 care provider is not unduly influenced by a pharmaceutical or medical
32 device manufacturing company's sales personnel;

33 (3) "Charitable donation" means the provision of financial support
34 to a nonprofit organization, as described in Section 501(c)(3) of the
35 Internal Revenue Code of 1986, or any subsequent corresponding
36 internal revenue code of the United States, as from time to time
37 amended or the in-kind provision of prescription drugs, biologics or
38 medical devices for charity care of patients;

39 (4) "Conference" or "meeting" means any convening where
40 responsibility for and control over the selection of content, faculty,
41 educational methods, materials and venue belong to the event's
42 organizers in accordance with their guidelines, held in a venue that is
43 appropriate and conducive to informational communication and
44 training about medical information, where (A) the gathering is
45 primarily dedicated, in both time and effort, to promoting objective
46 scientific and educational activities and discourse and one or more
47 educational presentations are the primary reason for the gathering,
48 and (B) the main purpose for bringing attendees together is to further
49 their knowledge on the topic or topics being presented;

50 (5) "Covered recipient" means a person authorized to prescribe,
51 dispense or purchase prescription drugs or medical devices in this

52 state, including a hospital, nursing home, pharmacist, health benefit
53 plan administrator or a health care provider. "Covered recipient" does
54 not include a bona fide employee of a pharmaceutical or medical
55 device manufacturing company or a consumer who purchases
56 prescription drugs or medical devices;

57 (6) "Department" means the Department of Consumer Protection;

58 (7) "Health care provider" means a person who prescribes
59 prescription drugs for any person and is licensed to provide health
60 care in this state, or a partnership or corporation comprised of such
61 persons, or an officer, employee, agent or contractor of such person
62 acting in the course and scope of his employment, agency or contract
63 related to or in support of the provision of health care to individuals.
64 "Health care provider" does not include hospitals and full-time
65 employees and members of the board of directors of pharmaceutical or
66 medical device manufacturers;

67 (8) "Hospital setting" means (A) a hospital, (B) academic medical
68 center, or (C) pharmaceutical or medical device specialized training
69 facility, where the facility, as certified by the pharmaceutical or
70 medical device manufacturing company to the Department of
71 Consumer Protection, is specifically designed to (i) approximate the
72 conditions of a surgical suite or a working clinical laboratory; or (ii)
73 provide medical training on large or technical medical devices, such as
74 surgical equipment, implants and imaging and clinical laboratory
75 equipment;

76 (9) "Medical device" means an instrument, apparatus, implement,
77 machine, contrivance, implant, in vitro reagent or other similar or
78 related article, including any component, part or accessory, that is: (A)
79 Recognized in the official National Formulary or the United States
80 Pharmacopeia or any supplement thereto; (B) intended for use in the
81 diagnosis of disease or other conditions or in the cure, mitigation,
82 treatment or prevention of disease, in persons or animals; or (C)
83 intended to affect the structure or function of the body of a person or

84 animal, and that does not achieve its primary intended purposes
85 through chemical action within or on such body and that is not
86 dependent upon being metabolized for the achievement of its primary
87 intended purposes;

88 (10) "Nonfaculty" means a health care provider who does not serve
89 as a speaker or provide actual and substantive services as a faculty
90 organizer or academic program consultant for a continuing medical
91 education event, third-party scientific or educational conference or
92 professional meeting;

93 (11) "Person" means a business, individual, corporation, union,
94 association, firm, partnership, committee or other organization;

95 (12) "Pharmaceutical or medical device manufacturer agent" means
96 a person who, while employed by or under contract with a
97 pharmaceutical or medical device manufacturing company, engages in
98 detailing, promotional activities or other marketing of prescription
99 drugs, biologics or medical devices in this state to any physician,
100 hospital, nursing home, pharmacist, health benefits plan administrator,
101 other health care provider or person authorized to prescribe, dispense
102 or purchase prescription drugs, biologics or medical devices.
103 "Pharmaceutical or medical device manufacturer agent" does not
104 include: (A) A licensed pharmacist, (B) a licensed physician or any
105 other licensed health care provider with authority to prescribe
106 prescription drugs, biologics or medical devices who is acting within
107 the ordinary scope of the practice for which he or she is licensed, (C) a
108 wholesale drug distributor registered with the department pursuant to
109 section 21a-70 of the general statutes, (D) a representative of such
110 distributor who promotes or otherwise markets the services of the
111 wholesale drug distributor in connection with a prescription drug, or
112 (E) a retail pharmacy licensed in this state, provided such person is not
113 engaging in such practices while employed by or under contract with a
114 pharmaceutical or medical device manufacturing company;

115 (13) "Pharmaceutical or medical device manufacturing company"

116 means any entity that: (A) Is engaged in the production, preparation,
117 propagation, compounding, conversion or processing of prescription
118 drugs, biologics or medical devices, either directly or indirectly, by
119 extraction from substances of natural origin or independently by
120 means of chemical synthesis or by a combination of extraction and
121 chemical synthesis; or (B) is directly engaged in the packaging,
122 repackaging, labeling, relabeling or distribution of prescription drugs,
123 biologics or medical devices. "Pharmaceutical or medical device
124 manufacturing company" does not include a health care provider,
125 physician practice, home health agency, hospital licensed in this state,
126 wholesale drug distributor licensed in this state or a retail pharmacy
127 licensed in this state; and

128 (14) "Prescription drugs" means drugs upon which the
129 manufacturer or distributor has placed or is required by federal law
130 and regulations to place the following or a comparable warning:
131 "Caution: Federal law prohibits dispensing without prescription".

132 Sec. 2. (NEW) (*Effective July 1, 2010*) (a) Each pharmaceutical or
133 medical device manufacturing company that employs or contracts
134 with a pharmaceutical or medical device manufacturer agent shall: (1)
135 Adopt a marketing code of conduct in compliance with the provisions
136 of sections 1 to 7, inclusive, of this act; (2) on or before July 1, 2011, and
137 annually thereafter, submit to the department a copy of its marketing
138 code; and (3) on or before July 1, 2011, and annually thereafter, submit
139 to the department a description of its training program to provide
140 regular training to appropriate employees including, but not limited
141 to, all sales and marketing staff, on the marketing code of conduct. The
142 training program shall ensure that all representatives who are
143 employed by or acting on behalf of a pharmaceutical or medical device
144 manufacturing company and who visit health care providers have
145 sufficient knowledge of the marketing code of conduct, general science
146 and product-specific information in order to provide accurate, up-to-
147 date information, consistent with state law and federal Food and Drug
148 Administration requirements. The training program shall also provide
149 for regular assessments of persons who are employed by or acting on

150 behalf of the company to ensure that such persons comply with the
151 provisions of sections 1 to 7, inclusive, of this act and other relevant
152 company policies.

153 (b) In addition to the requirements prescribed in subsection (a) of
154 this section, on or before July 1, 2011, and annually thereafter, each
155 pharmaceutical or medical device manufacturing company that
156 employs or contracts with a pharmaceutical or medical device
157 manufacturer agent shall (1) certify to the department, to the best of
158 the company's knowledge, information and belief that it is in
159 compliance with the provisions of sections 1 to 7, inclusive, of this act;
160 (2) submit to the department policies and procedures for investigating
161 noncompliance with the provisions of sections 1 to 7, inclusive, of this
162 act, taking corrective action in response to noncompliance and
163 reporting instances of noncompliance to the appropriate state
164 authorities; and (3) submit to the department the name, title, address,
165 telephone number and electronic mail address of the compliance
166 officer it has identified as responsible for certifying compliance with
167 the provisions of sections 1 to 7, inclusive, of this act and
168 implementing, monitoring and enforcing the company's marketing
169 code of conduct.

170 (c) Each pharmaceutical or medical device manufacturing company
171 that uses prescriber data unrelated to the identity of a patient to
172 facilitate communications with health care providers shall (1) maintain
173 the confidential nature of prescriber data; (2) develop policies
174 regarding the use of the data; (3) educate company employees and
175 pharmaceutical or medical device manufacturer agents concerning
176 such policies and designate an internal contact person to handle
177 inquiries regarding the use of the data; (4) identify appropriate
178 disciplinary actions for misuse of the data; and (5) comply with the
179 request of any health care provider who requests that prescriber data
180 not be made available to company sales representatives. Prior to
181 utilizing health care provider prescriber data for marketing purposes,
182 a pharmaceutical or medical device manufacturing company shall give
183 health care providers the opportunity to request that their prescriber

184 data be withheld from company sales representatives and not be used
185 for marketing purposes.

186 (d) Nothing in subsection (c) of this section shall prohibit
187 pharmaceutical or medical device manufacturing companies from
188 using prescriber data to impart important safety and risk information
189 to prescribers of a particular drug or device, conduct research, comply
190 with federal Food and Drug Administration mandated risk
191 management plans that require manufacturers to identify and interact
192 with health care providers who prescribe certain drugs or devices or
193 track adverse events of marketed prescription drugs, biologics or
194 devices.

195 (e) In all speaker and commercial consultant contracts,
196 pharmaceutical or medical device manufacturing companies shall
197 require any health care provider who is a member of a committee that
198 sets formularies or develops clinical guidelines and also serves as a
199 speaker or commercial consultant for the company to disclose to the
200 committee the nature and existence of the provider's relationship with
201 the company. The disclosure requirement shall extend for not less than
202 two years following the date of the termination of any speaker or
203 consultant arrangement.

204 (f) Not later than July 1, 2011, and annually thereafter, each
205 pharmaceutical and medical device manufacturing company shall
206 certify to the department that the company has external verification
207 procedures in place to monitor compliance with the provisions of
208 sections 1 to 7, inclusive, of this act.

209 Sec. 3. (NEW) (*Effective July 1, 2010*) (a) Except as provided in
210 sections 4 and 5 of this act, no pharmaceutical or medical device
211 manufacturing company that employs or contracts with a
212 pharmaceutical or medical device manufacturer agent may provide or
213 pay for meals for health care providers that are (1) part of an
214 entertainment or recreational event; (2) offered without an
215 informational presentation made by a pharmaceutical or medical

216 device marketing agent or without such an agent being present; (3)
217 offered, consumed or provided outside of the health care provider's
218 office or a hospital setting; or (4) provided to a healthcare provider's
219 spouse or other guest.

220 (b) Meals provided to health care providers that are otherwise in
221 compliance with the provisions of subsection (a) of this section shall be
222 modest and occasional in nature.

223 Sec. 4. (NEW) (*Effective July 1, 2010*) (a) No pharmaceutical or
224 medical device manufacturing company that employs or contracts
225 with a pharmaceutical or medical device manufacturer agent may
226 provide: (1) Financial support for the costs of travel, lodging or other
227 personal expenses of nonfaculty health care providers attending any
228 continuing medical education event, third-party scientific or
229 educational conference or professional meetings, either directly to the
230 individuals participating in the event or indirectly to the event's
231 sponsor; (2) funding to compensate for the time spent by health care
232 providers participating in any continuing medical education event,
233 third-party scientific or educational conferences or professional
234 meetings; (3) payment for meals directly to a health care provider at
235 any continuing medical education event, third-party scientific or
236 educational conferences or professional meetings, except that a
237 continuing medical education provider or conference or meeting
238 organizer may, at its own discretion, apply any financial support
239 provided by a pharmaceutical or medical device manufacturing
240 company for the event to provide meals for all participants; or (4)
241 sponsorship or payment for continuing medical education or
242 independent medical education, that does not meet the Standards for
243 Commercial Support as established by the Accreditation Council for
244 Continuing Medical Education or equivalent commercial support
245 standards of the relevant continuing education accrediting body.

246 (b) A pharmaceutical or medical device manufacturing company
247 shall separate its continuing medical education grant-making functions
248 from its sales and marketing divisions.

249 (c) A pharmaceutical or medical device manufacturing company
250 shall not provide any advice or guidance to the continuing medical
251 education provider regarding the content or faculty for a particular
252 continuing medical education program funded by the company.

253 (d) Nothing in sections 1 to 7, inclusive, of this act shall prohibit: (1)
254 Compensation or reimbursement made to a health care provider
255 serving as a speaker or providing actual and substantive services as a
256 faculty organizer or academic program consultant for a continuing
257 medical education event, third-party scientific or educational
258 conference or professional meeting, provided the payment is
259 reasonable, based on fair market value and complies with the
260 standards for commercial support as established by the relevant
261 accreditation entity; (2) sponsorship or payment for any portion of a
262 third-party scientific or educational conference, charitable conference
263 or meeting or professional meeting, where the payment is made
264 directly to the conference or meeting organizers; or (3) the use of hotel
265 facilities, convention center facilities or other special event venues for
266 continuing medical education or other third-party scientific,
267 educational or professional meetings or conferences.

268 Sec. 5. (NEW) (*Effective July 1, 2010*) (a) No pharmaceutical or
269 medical device manufacturing company that employs or contracts
270 with a pharmaceutical or medical device manufacturer agent may
271 provide: (1) Entertainment or recreational items of any value,
272 including, but not limited to, tickets to the theater, concerts or sporting
273 events, sporting equipment or leisure or vacation trips, to any health
274 care provider who is not a salaried employee of the pharmaceutical or
275 medical device manufacturing company; (2) payments of any kind,
276 including cash or cash equivalents, equity, in kind or tangible items,
277 including any complimentary items such as pens, coffee mugs or gift
278 cards to health care providers either directly or indirectly, except as
279 compensation for bona fide services; or (3) any grants, scholarships,
280 subsidies, supports, consulting contracts or educational or practice
281 related items in exchange for prescribing, disbursing or using
282 prescription drugs, biologics or medical devices or for a commitment

283 to continue prescribing, disbursing or using prescription drugs,
284 biologics or medical devices.

285 (b) Nothing in this section shall prohibit: (1) Reasonable
286 compensation for bona fide services or the reimbursement of other
287 reasonable out-of-pocket costs incurred by the health care provider
288 directly as a result of the performance of such services, where the
289 compensation and reimbursement is specified in, and paid for under, a
290 written agreement; (2) payment or reimbursement for the reasonable
291 expenses, including travel and lodging-related expenses necessary for
292 technical training of health care providers on the use of a medical
293 device if the commitment to provide such expenses and the amounts
294 or categories of reasonable expenses to be paid are described in the
295 written agreement between the health care provider and the device
296 vendor for the purchase of the device; (3) the provision of items that
297 are designed for the education of health care providers, such as
298 pamphlets, brochures and posters, provided the value of such items
299 does not exceed one hundred dollars and such items have no value to
300 the health care provider outside of his or her professional
301 responsibility; (4) the provision, distribution, dissemination or receipt
302 of peer reviewed academic, scientific or clinical information; (5) the
303 purchase of advertising in peer reviewed academic, scientific or
304 clinical journals; (6) the provision of prescription drugs to a health care
305 provider solely and exclusively for use by the health care provider's
306 patients; (7) the provision of reasonable quantities of medical device
307 demonstration and evaluation units provided to a health care provider
308 to assess the appropriate use and functionality of the product and
309 determine whether or not and when to use or recommend the product
310 in the future; (8) the provision of medical text books or anatomical
311 models that are designed for the education of health care providers; (9)
312 the provision of price concessions, such as rebates or discounts, in the
313 normal course of business; (10) the provision of reimbursement
314 information regarding products, including (A) identifying appropriate
315 coverage, coding or billing of products, (B) procedures for using such
316 products and information, in support of accurate and responsible

317 billing to Medicare and other payors, and (C) information designed to
318 offer technical or other support intended to aid in the appropriate and
319 efficient use or installation of products, except that such technical or
320 other support shall not be offered or provided for the purpose of
321 inducing health care providers to purchase, lease, recommend, use or
322 arrange for the purchase, lease or prescription of such products; (11)
323 the provision of payments or the provision of free outpatient
324 prescription drugs to health care providers for the benefit of low
325 income individuals, through established patient assistance programs,
326 provided the program meets the criterion for a permissible program in
327 accordance with the relevant published guidance available from the
328 Office of the Inspector General of the United States Department of
329 Health and Human Services, or is otherwise permitted under
330 applicable federal laws and regulations including, but not limited to,
331 42 USC 1320a-7b; or (12) the provision of charitable donations
332 provided the donation (A) is not provided in exchange for prescribing,
333 disbursing or using prescription drugs, biologics or medical devices or
334 for a commitment to continue prescribing, disbursing or using
335 prescription drugs, biologics or medical devices, and (B) does not
336 otherwise violate the provisions of sections 1 to 7, inclusive, of this act.

337 Sec. 6. (NEW) (*Effective July 1, 2010*) No pharmaceutical or medical
338 device manufacturing company shall discharge, refuse to hire, refuse
339 to serve or in any manner retaliate or take any adverse action against
340 any employee, applicant, health care provider or covered recipient if
341 such employee, applicant, health care provider or covered recipient
342 takes or has taken any action in furtherance of the enforcement of the
343 provisions of sections 1 to 7, inclusive, of this act.

344 Sec. 7. (NEW) (*Effective July 1, 2010*) (a) A person who knowingly
345 and wilfully violates any provision of sections 2 to 6, inclusive, of this
346 act shall be liable for a civil fine of not more than five thousand dollars
347 for each transaction, occurrence or event that constitutes a violation of
348 sections 2 to 6, inclusive, of this act.

349 (b) The Department of Consumer Protection may assess a civil fine

350 in accordance with the provisions of subsection (a) of this section.
351 Upon request of the Commissioner of Consumer Protection, the
352 Attorney General may petition the superior court for collection of such
353 fine and such equitable and injunctive relief as the court deems
354 appropriate.

This act shall take effect as follows and shall amend the following sections:		
---	--	--

Section 1	<i>July 1, 2010</i>	New section
Sec. 2	<i>July 1, 2010</i>	New section
Sec. 3	<i>July 1, 2010</i>	New section
Sec. 4	<i>July 1, 2010</i>	New section
Sec. 5	<i>July 1, 2010</i>	New section
Sec. 6	<i>July 1, 2010</i>	New section
Sec. 7	<i>July 1, 2010</i>	New section

PH *Joint Favorable Subst.*

GL *Joint Favorable*